GLP-1 Weight Loss Drug Coverage Is Now a Dealbreaker for Many Job Seekers, Especially Gen Z

Getting a job offer used to come down to salary, vacation days, and a good 401(k). Now, however, workers are asking something very different before accepting: Does this job cover my weight loss medication?

That shift is real. Moreover, the numbers back it up.

A ZipHealth survey of over 1,000 workers found that 47% of Gen Z respondents said GLP-1 coverage would change which job they pick. Specifically, this applied when two offers were otherwise equal. Meanwhile, millennials came in at 35% and Gen X at 36%. Still, the gap is telling. Younger workers are therefore treating this benefit like paid time off or remote work flexibility.

Furthermore, it gets more interesting. Overall, 54% of workers said they’d give up another perk just to get GLP-1 coverage. Additionally, 7% said they’d take a pay cut for it. Among Gen Z, that number rises to 9%. Consequently, that’s a real sacrifice. It clearly shows how much these medications mean to people right now.

So what exactly are GLP-1 drugs? The most recognized names include Wegovy, Ozempic, and Mounjaro. Originally, these were created to treat type 2 diabetes. However, doctors soon noticed they also caused significant weight loss. As a result, the FDA has since approved several for obesity treatment in adults who qualify. Then in late 2024, the FDA approved a pill version of Wegovy. Therefore, patients no longer need an injection. That was consequently a major step for accessibility.

Despite this momentum, most employers still don’t fully cover these drugs for weight loss. Specifically, a 2025 survey found that 55% of employers cover GLP-1s for diabetes. Yet only 36% cover them for weight loss. Similarly, a separate KFF survey put the figure even lower, around 20% of large employers. However, companies with 5,000 or more employees were more generous, reaching about 43%.

Ultimately, the hesitation comes down to cost. For instance, around 34% of non-elderly adults on employer-sponsored health plans would medically qualify for a GLP-1 drug. That’s roughly 36 million people. Furthermore, GLP-1 weight loss claims jumped from 6.9% of total drug spend in 2023 to 10.5% in 2025. Additionally, more than a quarter of employers said these drugs now make up over 15% of their annual drug costs.

As a result, those figures have pushed some companies to scale back. Several employers who once covered GLP-1s for weight management have therefore narrowed the rules. Now they only cover employees with a type 2 diabetes diagnosis. It’s a cost control move. Nevertheless, it leaves many workers without access.

Even so, demand from employees isn’t fading. In fact, a 2026 Harris Poll found that 65% of employed adults would be more likely to use a GLP-1 drug if their employer helped cover the cost. That’s an important finding. For many people, therefore, it’s not just about wanting the medication. Rather, it’s about being able to afford it.

For employers, this is no longer a niche benefits question. Increasingly, workers are factoring GLP-1 coverage into job decisions. As these medications become easier to access and more widely known, that trend will only grow stronger. Those interested in understanding prescription drug coverage options or learning more about managing weight through medical treatment can find trusted guidance through federal health resources.